临床研究
ENGLISH ABSTRACT
不同抗真菌药物治疗真菌性角膜炎有效性和安全性的网状meta分析
庞金鼎
韦振宇
曹凯
徐西占
梁庆丰
作者及单位信息
·
DOI: 10.3760/cma.j.cn115989-20230408-00124
A network meta-analysis of the efficacy and safety of different antifungal drugs for fungal keratitis
Pang Jinding
Wei Zhenyu
Cao Kai
Xu Xizhan
Liang Qingfeng
Authors Info & Affiliations
Pang Jinding
Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing 100730, China
Wei Zhenyu
Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing 100730, China
Cao Kai
Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing 100730, China
Xu Xizhan
Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing 100730, China
Liang Qingfeng
Beijing Institute of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Sciences Key Lab, Beijing 100730, China
·
DOI: 10.3760/cma.j.cn115989-20230408-00124
0
0
0
0
0
0
PDF下载
APP内阅读
摘要

目的系统评价不同抗真菌药物治疗真菌性角膜炎(FK)的有效性及安全性。

方法采用网状meta分析方法,检索PubMed、Cochrane Library、Embase、Web of Science共4个数据库,检索时限为建库至2023年3月16日。由2名研究者遵循纳入和排除标准筛选随机对照试验(RCT)研究文献,完成质量评估和信息提取。采用Review Manager 5.4偏移风险评估工具进行文献质量评估,采用Stata 14.0软件对不同抗真菌药物治疗FK的治愈率、治愈时间、治疗前后视力变化及安全性进行网状meta分析。

结果最终纳入14项RCT研究,共1 681例患者。网状meta分析显示,在治愈率方面,0.2%洗必泰滴眼液、5%那他霉素+伏立康唑(口服)较其他药物显示出更好的疗效,累计排序曲线下面积(SUCRA)为86.1%和63.3%,且1%伏立康唑滴眼液治愈率低于0.2%洗必泰滴眼液、5%那他霉素滴眼液+伏立康唑(口服)、0.05%洗必泰滴眼液、0.1%洗必泰滴眼液、5%那他霉素滴眼液+酮康唑(口服)、5%那他霉素滴眼液,差异均有统计学意义(均 P<0.05);1%伏立康唑滴眼液、5%那他霉素+伏立康唑(口服)在治愈时间方面表现最好(SUCRA=66.9%、55.7%);5%那他霉素滴眼液、1%伏立康唑滴眼液和伏立康唑口服三联治疗在改善视力和安全性方面优于其他药物(SUCRA分别为74.8%、79.7%)。在安全性方面,5%那他霉素滴眼液优于1%伏立康唑滴眼液和0.2%洗必泰滴眼液,差异均有统计学意义(均 P<0.05)。此外,此次分析可能存在潜在的发表偏倚。

结论0.2%洗必泰滴眼液、1%伏立康唑滴眼液在FK治疗中具有较好的疗效,5%那他霉素滴眼液、1%伏立康唑滴眼液和伏立康唑口服三联治疗对FK患者具有较好的视力改善率及安全性。

真菌性角膜炎;药物治疗;网状meta分析
ABSTRACT

ObjectiveTo systematically evaluate the efficacy and safety of different antifungal medications for fungal keratitis (FK).

MethodsA network meta-analysis was conducted.Four databases including PubMed, Cochrane Library, Embase, Web of Science were searched.The publication period was from inception to March 16, 2023.Two researchers followed the inclusion and exclusion criteria to screen randomized controlled trial (RCT), completed the quality assessment and extracted the information.Literature quality assessment was performed using Review Manager 5.4 bias risk assessment tool, and network meta-analysis was performed using Stata 14.0 software for cure rate, healing time, visual acuity improvement and safety of different antifungal drugs for fungal keratitis.

ResultsA total of 14 RCTs involving 1 681 patients were finally included in this study.The network meta-analysis showed that 0.2% chlorhexidine eye drops and 5% natamycin eye drops+ oral voriconazole had better efficacy than other interventions in cure rate, and the surface under the cumulative ranking (SUCRA) were 86.1% and 63.3%, respectively.The cure rate of 1% voriconazole eye drops was lower than that of 0.2% chlorhexidine eye drops, 5% natamycin eye drops+ oral voriconazole, 0.05% chlorhexidine eye drops, 0.1% chlorhexidine eye drops, 5% natamycin eye drops+ oral ketoconazole and 5% natamycin eye drops, showing statistically significant differences (all at P<0.05).1% voriconazole eye drops and 5% natamycin eye drops+ oral voriconazole showed better efficacy than other interventions in terms of healing time (SUCRA=66.9%, 55.7%).The combination of 5% natamycin eye drops, 1% voriconazole eye drops and oral voriconazole showed a better efficacy than others in improving visual acuity and safety (SUCRA=74.8%, 79.7%).For safety, 5% natamycin eye drops was superior to 1% voriconazole eye drops and 0.2% chlorhexidine eye drops, with statistically significant differences (both at P<0.05).In addition, there may be potential publication bias in this analysis.

Conclusions0.2% chlorhexidine eye drops and 1% voriconazole eye drops are effective in the treatment of FK.The combination use of 5% natamycin eye drops, 1% voriconazole eye drops and oral voriconazole can improve visual acuity and had good safety.

Fungal keratitis;Drug therapy;Network meta-analysis
Liang Qingfeng, Email: mocdef.3ab61ykculfql
引用本文

庞金鼎,韦振宇,曹凯,等. 不同抗真菌药物治疗真菌性角膜炎有效性和安全性的网状meta分析[J]. 中华实验眼科杂志,2024,42(07):629-637.

DOI:10.3760/cma.j.cn115989-20230408-00124

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价
真菌性角膜炎(fungal keratitis,FK)是一种发病率较高的致盲眼病,占感染性角膜炎的50%以上 [ 1 ]。在发展中国家,真菌已成为感染性角膜炎常见的病原体之一,每年新发病例超过100万例 [ 2 , 3 , 4 ]。临床上,FK表现为慢性、迁延不愈的角膜溃疡,且预后较差,30%~45%的FK患者在治疗晚期需行角膜移植,10%~25%的患者需摘除眼球,严重影响患者的视力和生活质量 [ 5 , 6 ]。药物和手术是FK治疗的主要方式,眼部抗真菌药物包括多烯类(如那他霉素、两性霉素B等)、三唑类(如伏立康唑、酮康唑等)和棘白菌素类(如米卡芬净、卡泊芬净等)。那他霉素滴眼液是美国食品药品监督管理局批准的唯一用于FK治疗的药物,具有广谱抗真菌活性,但其相对分子质量大、渗透性及溶解性差,影响了该药的临床治疗效果 [ 7 , 8 ]。除上述药物外,洗必泰滴眼液作为临时配置的抗真菌眼药也应用于临床FK的治疗,已取得一定的疗效 [ 9 ]。现有的meta分析仅将治疗FK药物进行两两比较 [ 10 , 11 , 12 ],暂未发现2种以上治疗措施之间比较的研究。网状meta分析是传统meta分析的拓展,能够同时比较2种以上干预措施 [ 13 ]。基于此,本研究采用网状meta分析方法,比较不同抗真菌药物在FK治疗中的效果,为临床医生选择更好的治疗方案提供参考。
试读结束,您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Ung L Acharya NR Agarwal T et al. Infectious corneal ulceration:a proposal for neglected tropical disease status[J]. Bull World Health Organ 201997(12)∶854856. DOI: 10.2471/BLT.19.232660 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
Prajna NV Srinivasan M Mascarenhas J et al. Visual impairment in fungal versus bacterial corneal ulcers 4 years after successful antimicrobial treatment[J]. Am J Ophthalmol 2019204124129. DOI: 10.1016/j.ajo.2019.03.010 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Mills B Radhakrishnan N Karthikeyan Rajapandian SG et al. The role of fungi in fungal keratitis[J/OL]. Exp Eye Res 2021202108372[2023-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/33249061. DOI: 10.1016/j.exer.2020.108372 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Brown L Leck AK Gichangi M et al. The global incidence and diagnosis of fungal keratitis[J/OL]. Lancet Infect Dis 202121(3)∶e49e57[2023-11-10]. http://pubmed.ncbi.nlm.nih.gov/33645500. DOI: 10.1016/S1473-3099(20)30448-5 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Sun S Lui Q Han L et al. Identification and characterization of fusarium proliferatum,a new species of fungi that cause fungal keratitis[J/OL]. Sci Rep 20188(1)∶4859[2023-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/29559666. DOI: 10.1038/s41598-018-23255-z .
返回引文位置Google Scholar
百度学术
万方数据
[6]
Bourcier T Sauer A Dory A et al. Fungal keratitis[J/OL]. J Fr Ophtalmol 201740(9)∶e307e313[2023-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/28987448. DOI: 10.1016/j.jfo.2017.08.001 .
返回引文位置Google Scholar
百度学术
万方数据
[7]
Sharma N Bagga B Singhal D et al. Fungal keratitis:a review of clinical presentations,treatment strategies and outcomes[J]. Ocul Surf 2022242230. DOI: 10.1016/j.jtos.2021.12.001 .
返回引文位置Google Scholar
百度学术
万方数据
[8]
Zhao X Tong Y Wang X et al. Comparison of the ocular penetration and pharmacokinetics between natamycin and voriconazole after topical instillation in rabbits[J]. J Ocul Pharmacol Ther 201834(6)∶460467. DOI: 10.1089/jop.2017.0139 .
返回引文位置Google Scholar
百度学术
万方数据
[9]
Oliveira Dos Santos C Hanemaaijer NM Ye J et al. Chlorhexidine for the treatment of fusarium keratitis:a case series and mini review[J/OL]. J Fungi (Basel) 20217(4)∶255[2023-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/33805369. DOI: 10.3390/jof7040255 .
返回引文位置Google Scholar
百度学术
万方数据
[10]
Qiu S Zhao GQ Lin J et al. Natamycin in the treatment of fungal keratitis:a systematic review and meta-analysis[J]. Int J Ophthalmol 20158(3)∶597602. DOI: 10.3980/j.issn.2222-3959.2015.03.29 .
返回引文位置Google Scholar
百度学术
万方数据
[11]
FlorCruz NV Evans JR . Medical interventions for fungal keratitis[J/OL]. Cochrane Database Syst Rev 20152015(4)∶CD004241[2023-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/25855311. DOI: 10.1002/14651858.CD004241.pub4 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Retamal J Ordenes-Cavieres G Grau-Diez A Natamycin versus voriconazole for fungal keratitis[J/OL]. Medwave 201818(8)∶e7388[2023-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/30562337. DOI: 10.5867/medwave.2018.08.7387 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Chaimani A Higgins JP Mavridis D et al. Graphical tools for network meta-analysis in Stata[J/OL]. PLoS One 20138(10)∶e76654[2023-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/24098547. DOI: 10.1371/journal.pone.0076654 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Shim S Yoon BH Shin IS et al. Network meta-analysis:application and practice using Stata[J/OL]. Epidemiol Health 201739e2017047[2023-11-10]. http://www.ncbi.nlm.nih.gov/pubmed/29092392. DOI: 10.4178/epih.e2017047 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Rahman MR Minassian DC Srinivasan M et al. Trial of chlorhexidine gluconate for fungal corneal ulcers[J]. Ophthalmic Epidemiol 19974(3)∶141149. DOI: 10.3109/09286589709115721 .
返回引文位置Google Scholar
百度学术
万方数据
[16]
Rahman MR Johnson GJ Husain R et al. Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh[J]. Br J Ophthalmol 199882(8)∶919925. DOI: 10.1136/bjo.82.8.919 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Prajna NV Mascarenhas J Krishnan T et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis[J]. Arch Ophthalmol 2010128(6)∶672678. DOI: 10.1001/archophthalmol.2010.102 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Arora R Gupta D Goyal J et al. Voriconazole versus natamycin as primary treatment in fungal corneal ulcers[J]. Clin Exp Ophthalmol 201139(5)∶434440. DOI: 10.1111/j.1442-9071.2010.02473.x .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Parchand S Gupta A Ram J et al. Voriconazole for fungal corneal ulcers[J/OL]. Ophthalmology 2012119(5)∶1083[2023-11-16]. http://www.ncbi.nlm.nih.gov/pubmed/22551602. DOI: 10.1016/j.ophtha.2011.11.034 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Prajna NV Krishnan T Mascarenhas J et al. The mycotic ulcer treatment trial:a randomized trial comparing natamycin vs voriconazole[J]. JAMA Ophthalmol 2013131(4)∶422429. DOI: 10.1001/jamaophthalmol.2013.1497 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
Sharma N Chacko J Velpandian T et al. Comparative evaluation of topical versus intrastromal voriconazole as an adjunct to natamycin in recalcitrant fungal keratitis[J]. Ophthalmology 2013120(4)∶677681. DOI: 10.1016/j.ophtha.2012.09.023 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Rajaraman R Bhat P Vaidee V et al. Topical 5% natamycin with oral ketoconazole in filamentous fungal keratitis:a randomized controlled trial[J]. Asia Pac J Ophthalmol (Phila) 20154(3)∶146150. DOI: 10.1097/APO.0000000000000035 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Sharma S Das S Virdi A et al. Re-appraisal of topical 1% voriconazole and 5% natamycin in the treatment of fungal keratitis in a randomised trial[J]. Br J Ophthalmol 201599(9)∶11901195. DOI: 10.1136/bjophthalmol-2014-306485 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Prajna NV Krishnan T Rajaraman R et al. Effect of oral voriconazole on fungal keratitis in the mycotic ulcer treatment trial Ⅱ (MUTT Ⅱ):a randomized clinical trial[J]. JAMA Ophthalmol 2016134(12)∶13651372. DOI: 10.1001/jamaophthalmol.2016.4096 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
Sharma N Singhal D Maharana PK et al. Comparison of oral voriconazole versus oral ketoconazole as an adjunct to topical natamycin in severe fungal keratitis:a randomized controlled trial[J]. Cornea 201736(12)∶15211527. DOI: 10.1097/ICO.0000000000001365 .
返回引文位置Google Scholar
百度学术
万方数据
[26]
Narayana S Krishnan T Ramakrishnan S et al. Mycotic antimicrobial localized injection:a randomized clinical trial evaluating intrastromal injection of voriconazole[J]. Ophthalmology 2019126(8)∶10841089. DOI: 10.1016/j.ophtha.2019.03.020 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Saluja G Sharma N Agarwal R et al. Comparison of safety and efficacy of intrastromal injections of voriconazole,amphotericin b and natamycin in cases of recalcitrant fungal keratitis:a randomized controlled trial[J]. Clin Ophthalmol 20211524372446. DOI: 10.2147/OPTH.S301878 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Hoffman JJ Yadav R Sanyam SD et al. Topical chlorhexidine 0.2% versus topical natamycin 5% for the treatment of fungal keratitis in nepal:a randomized controlled noninferiority trial[J]. Ophthalmology 2022129(5)∶530541. DOI: 10.1016/j.ophtha.2021.12.004 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
Rouse B Chaimani A Li T Network meta-analysis:an introduction for clinicians[J]. Intern Emerg Med 201712(1)∶103111. DOI: 10.1007/s11739-016-1583-7 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
McDonnell G Russell AD . Antiseptics and disinfectants:activity,action,and resistance[J]. Clin Microbiol Rev 199912(1)∶147179. DOI: 10.1128/CMR.12.1.147 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
Maycock NJ Jayaswal R Update on Acanthamoeba keratitis:diagnosis,treatment,and outcomes [J]. Cornea 201635(5)∶713720. DOI: 10.1097/ICO.0000000000000804 .
返回引文位置Google Scholar
百度学术
万方数据
[32]
Oliveira Dos Santos C Kolwijck E van der Lee HA et al. In vitro activity of chlorhexidine compared with seven antifungal agents against 98 fusarium isolates recovered from fungal keratitis patients [J/OL]. Antimicrob Agents Chemother 201963(8)∶e0266918[2023-11-16]. http://www.ncbi.nlm.nih.gov/pubmed/31182529. DOI: 10.1128/AAC.02669-18 .
返回引文位置Google Scholar
百度学术
万方数据
[33]
Kunt Z Yağmur M Kandemir H et al. In vitro efficacy of chlorhexidine and a riboflavin/uva combination on fungal agents of keratitis [J]. Curr Eye Res 202045(1)∶711. DOI: 10.1080/02713683.2019.1652916 .
返回引文位置Google Scholar
百度学术
万方数据
[34]
Arunga S Mbarak T Ebong A et al. Chlorhexidine gluconate 0.2% as a treatment for recalcitrant fungal keratitis in Uganda:a pilot study[J/OL]. BMJ Open Ophthalmol 20216(1)∶e000698[2023-11-16]. http://www.ncbi.nlm.nih.gov/pubmed/34368461. DOI: 10.1136/bmjophth-2020-000698 .
返回引文位置Google Scholar
百度学术
万方数据
[35]
Pérez-Cantero A López-Fernández L Guarro J et al. Azole resistance mechanisms in Aspergillus:update and recent advances [J/OL]. Int J Antimicrob Agents 202055(1)∶105807[2023-11-16]. http://www.ncbi.nlm.nih.gov/pubmed/31542320. DOI: 10.1016/j.ijantimicag.2019.09.011 .
返回引文位置Google Scholar
百度学术
万方数据
[36]
te Welscher YM ten Napel HH Balagué MM et al. Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane[J]. J Biol Chem 2008283(10)∶63936401. DOI: 10.1074/jbc.M707821200 .
返回引文位置Google Scholar
百度学术
万方数据
[37]
Hariprasad SM Mieler WF Holz ER et al. Determination of vitreous,aqueous,and plasma concentration of orally administered voriconazole in humans[J]. Arch Ophthalmol 2004122(1)∶4247. DOI: 10.1001/archopht.122.1.42 .
返回引文位置Google Scholar
百度学术
万方数据
[38]
Levine MT Chandrasekar PH . Adverse effects of voriconazole:over a decade of use[J]. Clin Transplant 201630(11)∶13771386. DOI: 10.1111/ctr.12834 .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
梁庆丰,Email: mocdef.3ab61ykculfql
B

庞金鼎:采集数据、起草文章、分析/解释数据;韦振宇:采集数据、分析/解释数据、对文章的知识性内容作批评性审阅;曹凯、徐西占:统计分析及研究指导;梁庆丰:酝酿和设计试验、指导研究、对文章的知识性内容作批评性审阅及定稿

C
所有作者均声明不存在利益冲突
D
国家重点研发计划 (2021YFC2301000)
评论 (0条)
注册
登录
时间排序
暂无评论,发表第一条评论抢沙发
MedAI助手(体验版)
文档即答
智问智答
机器翻译
回答内容由人工智能生成,我社无法保证其准确性和完整性,该生成内容不代表我们的态度或观点,仅供参考。
生成快照
文献快照

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持:

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号